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Abstract
Background:  Pulmonary  rehabilitation  (PR)  is  a  cornerstone  intervention  for  the  management
of patients  with  stable  chronic  obstructive  pulmonary  disease  (COPD).  However,  its  role  dur-
ing acute  exacerbations  (AECOPD)  is  controversial  since  most  studies  have  been  conducted  in
hospitalised  patients,  when  more  than  80%  of  AECOPD  are  managed  on  an  outpatient  basis.
This quasi-experimental  pilot  study  assessed  the  effects  of  a  community-based  PR  programme
during mild-to-moderate  AECOPD.
Methods:  Outpatients  were  recruited  from  hospitals  and  allocated  to  experimental  (EG)  or  con-
trol (CG)  groups.  EG  received  standard  medication  plus  3-weeks  of  PR.  The  CG  received  standard
medication.  Dyspnoea  (mMRC),  quadriceps  muscle  strength  (QMS),  functionality  (5-repetition
sit-to-stand  test)  and  impact  of  the  disease  (COPD  assessment  test  (CAT))  were  assessed  within
48 h  of  the  AECOPD  onset  and  after  PR.  Symptoms  of  dyspnoea  and  fatigue  (mBorg),  heart
and respiratory  (RR)  rates  and  peripheral  oxygen  saturation  (SpO2)  were  assessed  at  rest  and
monitored in  all  PR  sessions.  Need  for  hospitalisation  was  monitored  during  the  3-weeks.
Results: Twelve  patients  (69  ±  7  years,  FEV1 52  ±  27  pp)  in  the  EG  and  eleven  in  the  CG  (66  ±  9
years, FEV1 55  ±  22  pp)  were  enrolled.  The  EG  presented  signiﬁcant  improvements  on  QMS  (Pre
21.0 vs.  Post  25.0,  p  =  0.012),  CAT  (Pre  23.0  vs.  Post  14.5,  p  =  0.008),  symptoms  of  dyspnoea  at
rest (Pre  3.0  vs.  Post  1.0,  p  =  0.008),  SpO2 (Pre  94.0  vs.  Post  96.0,  p  =  0.031)  and  RR  (Pre  24.0
vs. Post  20.5,  p  =  0.004).  No  signiﬁcant  improvements  were  found  in  the  CG.Please  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
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Conclusion:  Adding  PR  to  the  management  of  mild-to-moderate  AECOPD  seems  to  result  in
improvements  on  parameters  usually  associated  with  an  increased  risk  of  re-exacerbation  and
poor prognosis.  Randomised  studies  with  larger  samples  are  needed  to  conﬁrm  these  results.
© 2019  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Antroduction
he  trajectory  of  chronic  obstructive  pulmonary  disease
COPD)  is  frequently  punctuated  by  exacerbations,  deﬁned
s  episodes  of  acute  worsening  of  respiratory  symptoms  that
esult  in  additional  therapy.1,2 Acute  exacerbations  of  COPD
AECOPD)  account  for  more  than  70%  of  all  COPD-related
osts3 and  are  mainly  responsible  for  patients’  clinical
eterioration.1 It  is  known  that  AECOPD  result  in  signiﬁ-
ant  decline  in  muscle  strength,  functional  capacity  and  lung
unction,  which  further  impairs  patients’  health-related
uality  of  life  (HRQoL)  and  increases  their  susceptibility  to
ore  exacerbations,  hospitalisations  and  death.1,2,4,5 There-
ore,  treatment  goals  for  patients  with  AECOPD  are  to
inimise  the  negative  impact  of  these  events  and  prevent
heir  recurrence.1
Pulmonary  rehabilitation  (PR)  is  a  well-established  inter-
ention  for  the  management  of  patients  with  stable  COPD.1,6
t  has  been  shown  to:  (i)  improve  exercise  capacity,  func-
ional  capacity,  muscle  strength  and  HRQoL;  (ii)  reduce
ymptoms,  hospitalisations  and  unscheduled  healthcare  vis-
ts;  and  (iii)  enhance  self-management  and  self-efﬁcacy.6
iven  these  beneﬁts  it  would  seem  reasonable  to  consider
R  as  a  management  strategy  for  AECOPD.7 However,  stud-
es  assessing  the  role  of  PR  during  AECOPD  have  shown
ontroversial  results;1,8 this  is  probably  related  to  the  set-
ings  in  which  the  PR  programmes  have  been  conducted
nd  the  disease  severity  of  patients  included.  Most  stud-
es  have  been  conducted  in  hospitalised  patients,3,9 who
resent  more  severe  exacerbations  and/or  more  severe
nderlying  disease  than  those  managed  on  an  outpatient
etting.1 Although  it  is  recognised  that  more  than  80%  of
ll  AECOPD  are  managed  on  an  outpatient  basis,1 only  a  few
tudies  have  conducted  PR  programmes  on  an  outpatient
etting.10--13 Additionally,  those  studies  did  not  start  their
ntervention  at  the  onset  of  the  AECOPD  but  shortly  after
he  AECOPD,10,11 included  patients  with  AECOPD  who  have
reviously  been  hospitalised,12,13 and  have  found  signiﬁcant
esults  in  different  outcomes  (e.g.,  exercise  capacity,10,12
RQoL,10--12 and  re-exacerbations13).  Thus,  the  potential
ole  of  PR  programmes  during  AECOPD  in  patients  man-
ged  on  an  outpatient  basis  is  not  yet  clariﬁed.  Moreover,
utpatient  basis  includes  community-based  PR  (i.e.,  PR  pro-
rammes  nearby  patients’  homes),  which  may  be  a  promising
pproach  to  overcoming  the  shortcomings  of  poor  access  and
ransport  to  PR,  especially  in  patients  with  AECOPD,  but  has
ardly  been  investigated.14,15Please  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol
Therefore,  this  pilot  study  aimed  to  explore  the  fea-
ibility  of  conducting  a  community-based  PR  programme
uring  AECOPD  and  assess  its  effects  on  patients’  symptoms,
s
g
iuscle  strength,  functionality,  impact  of  the  disease,
eripheral  oxygen  saturation  and  hospitalizations.
ethods
thics
pproval  for  this  study  was  obtained  from  the  ethics
ommittees  of  the  Administrac¸ão Regional  de  Saúde  do
entro,  I.P.  (3NOV’2016:64/2016),  Centro  Hospitalar  do
aixo  Vouga  (22MAR’2017:777638),  Hospital  Pedro  Hispano
17FEB’2017:10/CE/JAS)  and  Hospital  Distrital  da  Figueira
a  Foz  (18JUL’2017)  and  from  the  National  Data  Protection
ommittee  (8828/2016).  Written  informed  consents  were
btained  from  all  participants  before  any  data  collection.
tudy  design  and  participants
 quasi-experimental  study  was  conducted  in  outpatients
ith  AECOPD  recruited  from  three  main  hospitals  between
ovember  2016  and  December  2017.  Inclusion  criteria  were
iagnosis  of  AECOPD  according  to  the  Global  Initiative  for
hronic  Obstructive  Lung  Disease  (GOLD)  criteria.1 Exclusion
riteria  were:  (i)  hospitalisation;  (ii)  presence  of  severe  co-
xisting  cardiac,  respiratory,  neurological,  musculoskeletal,
r  signs  of  psychiatric  impairments;  (iii)  current  neoplasia  or
mmunological  disease  and  (v)  any  therapeutic  intervention
n  addition  to  standard  of  care.  Eligible  patients  were  iden-
iﬁed  by  pulmonologists  and  contacted  by  the  researchers,
ho  explained  the  purpose  of  the  study  and  asked  about
heir  willingness  to  participate.  An  appointment  with  the
esearchers  was  scheduled  within  48  h of  the  diagnosis  of
ECOPD  with  those  interested  in  participating.  Due  to  the
xploratory  nature  of  this  study  and  the  controversy  around
he  efﬁcacy  and  safety  of  conducting  PR  during  AECOPD,2 we
elt  that  randomising  patients  was  not  suitable.16 Like  other
tudies,17--19 patients  were  given  the  choice  of  treatment.
articipants  who  accepted  enrolment  in  the  PR  programme
ere  assigned  to  the  experimental  group  (EG),  the  remain-
ng  participants,  who  accepted  participation  in  the  study  but
id  not  want  to  be  enrolled  in  the  PR  programme,  composed
he  control  group  (CG).
ample  size
ccording  to  the  recommendations  for  adequate  sample.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
izes  to  conduct  pilot  studies,  twelve  participants  in  each
roup  would  be  needed  to  conduct  this  study.20 However,  as
t  is  known  that  dropout  rates  in  respiratory  interventions
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Community-based  pulmonary  rehabilitation  during  exacerba
are  around  30--35%,21 sixteen  patients  in  each  group  were
aimed  to  be  recruited.
Intervention
The  intervention  consisted  of  standard  medical  treatment
for  the  CG  (i.e.,  pharmacotherapy)  and  standard  medi-
cal  treatment  plus  a  community-based  PR  programme  for
the  EG.  The  community-based  PR  programme  was  per-
formed  twice  a  week  for  3  weeks.22,23 The  mean  duration
of  each  session  was  60  min  and  included  breathing  con-
trol  and  airway  clearance  techniques,  thoracic  expansion
and  mobility  exercises,  exercise  training  and  psychoeduca-
tional  support.3,24,25 Exercise  training  was  set  at  an  intensity
of  60--80%  of  patients’  maximum  estimated  heart  rate  and
symptoms  of  dyspnoea  and  perceived  exertion  were  main-
tained  between  4  and  6  at  the  modiﬁed  Borg  scale  (mBorg).
Psychoeducational  support  was  performed  using  ﬂyers  and
verbal  discussions.25,26 A  multidisciplinary  team  was  avail-
able  to  provide  additional  support.  Sessions  were  held  at
the  School  of  Health  Sciences,  University  of  Aveiro  (ESSUA)
or  at  patients’  home  by  a  physiotherapist  with  experience
in  respiratory  interventions.  A  detailed  description  of  the
intervention  protocol  can  be  found  in  Fig.  1.
Outcome  measures
Sociodemographic  (age,  gender),  anthropometric  (height,
weight,  body  mass  index  --  BMI)  and  general  clinical  data
(smoking  habits,  number  of  exacerbations  in  the  past  year,
medication  used  in  the  stable  and  exacerbated  period  of  the
disease,  long-term  oxygen,  non-invasive  ventilation,  comor-
bidities  and  physical  activity  levels)  were  collected  within
48  h  of  the  AECOPD  onset.  The  severity  of  comorbid  dis-
eases  was  recorded  and  scored  according  to  the  Charlson
Comorbidity  Index  (CCI):27 mild  (CCI  scores  of  1--2),  moder-
ate  (CCI  scores  of  3--4)  and  severe  (CCI  scores  ≥5).  Physical
activity  level  was  assessed  with  the  brief  physical  activity
assessment  tool.28,29 Additionally,  severity  of  airﬂow  limi-
tation  was  classiﬁed  based  on  the  most  recent  spirometry
from  the  patients’  clinical  notes,  performed  when  they  were
stable.1 Patients’  clinical  notes  were  checked  for  any  need
of  hospitalisation  and/or  unscheduled  healthcare  utilisation
during  the  3  weeks  of  intervention.
Outcomes  assessed  before  and  after  the  3  weeks  of  inter-
vention  were  dyspnoea  during  activities,  quadriceps  muscle
strength,  functionality  and  impact  of  the  disease.  Symp-
toms  of  dyspnoea  and  fatigue  at  rest,  peripheral  oxygen
saturation  (SpO2)  and  vital  signs  (i.e.,  respiratory  and  heart
rates)  were  assessed  before  and  after  the  intervention  and
also  monitored  in  all  PR  sessions.  All  assessments  were
conducted  by  a  trained  physiotherapist  following  the  stan-
dardised  order  described.
Dyspnoea  and  fatigue  were  assessed  by  asking  partici-
pants  to  rate  their  perceived  levels  of  these  symptoms
on  the  mBorg.30,31 The  MCID  established  for  dyspnoea
symptoms  in  the  mBorg  is  of  0.9  units  for  patients  withPlease  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol
AECOPD  receiving  pharmacological  treatment.32 Symptoms
of  dyspnoea  and  fatigue,  SpO2 and  vital  signs  (to  ensure
patients’  security  during  the  intervention7),  were  assessed
at  rest  whilst  participants  were  sitting  and  resting  for  at
s
c
d PRESS
 of  COPD  3
east  10  min.  Respiratory  rate  was  assessed  during  60  s  by
irect  observation  of  the  chest  wall.33 Heart  rate  and  SpO2
ere  collected  with  a  pulse  oximeter  (Pulsox  300i,  Kon-
ca  Minolta,  Tokyo,  Japan).  In  AECOPD,  a SpO2 <  90%  has
een  shown  to  have  high  sensitivity  and  speciﬁcity  to  detect
oth  hypoxaemia  (sensitivity  =  83.9%,  speciﬁcity  =  88.9%)
nd  hypercapnia  (sensitivity  =  71.3%,  speciﬁcity  =  76%),9,34
nd  has  been  positively  correlated  with  arterial  oxygen  sat-
ration  (r  =  0.91;  p  <  0.001).9
Dyspnoea  during  activities  was  assessed  with  the
odiﬁed  British  Medical  Research  Council  dyspnoea  ques-
ionnaire  (mMRC).35 This  is  a  simple,  valid  and  widely  used
nstrument  to  characterise  the  impact  of  dyspnoea  on  the
aily  activities  of  patients  with  COPD  that  relates  well  with
ther  measures  of  health  status  and  predicts  mortality  risk.1
ariations  of  0.6  units  have  been  recently  indicated  as  the
inimal  clinically  important  difference  (MCID)  for  patients
ith  AECOPD  after  pharmacological  treatment.32
Quadriceps  muscle  strength  was  measured  on  the  dom-
nant  side  during  an  isometric  contraction  with  a  handheld
ynamometer  (microFET2,  Hoggan  Health,  The  best  Salt
ake  City,  Utah).36 This  is  an  important  outcome  since
uadriceps  muscle  strength  is  an  independent  predictor
f  mortality  in  COPD37 and  is  usually  decreased  during
ECOPD.38
Functionality  was  assessed  with  the  ﬁve-repetition  sit-to-
tand  test  (5-STS)  according  to  the  protocol  of  Jones  et  al.39
 MCID  of  1.7  s  has  been  established  for  patients  with  stable
OPD  after  PR.39 According  to  the  authors  best  knowledge,
here  is  no  MCID  established  for  AECOPD.
Impact  of  the  disease  was  measured  with  the  COPD
ssessment  test  (CAT).  CAT  is  one  of  the  key  outcome  mea-
ures  recommended  by  the  GOLD1 to  assess  patients  with
OPD,  and  is  also  the  outcome  measure  presenting  more
obust  measurement  properties  during  AECOPD.9 A  MCID  of
 points  for  patients  with  AECOPD  receiving  pharmacological
reatment  has  been  established.40
ata  analysis
tatistical  analyses  were  performed  using  IBM  SPSS  Statistics
ersion  24.0  (IBM  Corporation,  Armonk,  NY,  USA)  and  plots
reated  using  GraphPad  Prism  version  5.01  (GraphPad  Soft-
are,  Inc.,  La  Jolla,  CA,  USA).  The  level  of  signiﬁcance  was
et  at  0.05.
Descriptive  statistics  were  used  to  describe  the  sample.
The  normality  of  the  data  was  explored  with
he  Shapiro--Wilk  test.  Then,  independent  t  tests,
ann--Whitney  U  tests  and  chi-squared  tests  were  used  to
ompare  sociodemographic,  anthropometric  and  general
linical  characteristics  between  groups  (i.e.,  EG  vs.  CG).
he  differences  between  pre-  and  post-intervention  assess-
ents,  per  group,  were  pooled  for  each  outcome  measure
nd  Mann--Whitney  U  tests  were  used  to  compare  groups.
omparisons  between  pre-  and  post-intervention  assess-
ents  within  each  group  were  performed  with  Wilcoxon.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
igned-rank  tests.
Whenever  possible,  the  number  and  percentage  of  parti-
ipants  in  each  group  that  improved  above  the  MCID  was
etermined  and  compared  with  chi-squared  tests.  Data
Please  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
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Figure  1  Intervention  protocol  for  the  3-week  community-based  pulmonary  rehabilitation  programme.
Adapted  from  Marques  et  al.25
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Slow  inspiratory  and
expiratory techniques* 
Active cy cle  of  brea thing
techniques* 
Warm up  (5 min)
Circ umdu ction  of uppe r li mbs (prog ression  1)
Lateral flexion  of the  trun k (prog ress ion  2
Step  in place)
Crun che s
Proprioceptive neuromuscular facilitation
diagona l (prog ression  3)
Squa ts
Cyc ling  or Step  (interval) or Walking  (10  min)   
Circumduction of upper limbs (progre ssion  1)
Lateral flexion  of the  trun k (prog ression  2)
Step  in place
Crun che s
Proprioceptive neuromuscular facilitation
diagona l (prog ression  3)
Lunges
Cyc ling  or Step  (interval) or Walking  (20  min)   
Tho racic mobil ity and
expan sion  exercises and
muscle streng th
(2x10  ea ch exercise)
Aerob ic training  
Flexibili ty/stretch exerc ises
(2-3x30 s ea ch exercise)
Upper limb abductors and  addu ctors
Knee  exten sors
Posterior cha in muscles
Uppe r limb abdu ctors and  addu ctors
Knee  exten sors
Posterior cha in muscles
“Morning  stretch”
Psychoedu cationa l suppo rt
(flyers) 
Smoking  cess ation  (if ap plicab le)
*Only applied if needed and ba sed  on  pu lmonary  au scultation  finding s.
Legend: EDIC, exercise with inspiratory controlled flow; ELTGOL, total slow expiration with glottis open in lateral po sture;  PEP, po sitive expiratory 
pressure.
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are  presented  as  mean  ±  standard  deviation  or  median
[interquartile  range].
Results
Thirty-ﬁve  outpatients  with  AECOPD  were  referred  for  possi-
ble  inclusion  in  the  study.  From  these,  three  were  excluded
due  to  the  presence  of  sequels  from  a  cerebrovascular
accident  that  impaired  her/his  ability  to  perform  the  assess-
ments  (n  =  1),  suffering  from  Parkinson’s  disease  (n  =  1)  and
interstitial  lung  disease  (n  =  1).  Thus,  32  patients  were
invited  to  participate  in  the  study  and  allocated  to  either
the  EG  or  CG.  Three  patients  in  the  EG  (1  due  to  incom-
patibility  of  schedules  and  2  no  reason  given)  and  six  in
the  CG  (2  due  to  incompatibility  of  schedules  and  4  no  rea-
son  given)  dropped  out  of  the  study.  Therefore,  23  patients
(19  males,  67.3  ±  8.0  years,  forced  expiratory  volume  in  1  s
57.2  ±  23.9%predicted),  12  in  the  EG  and  11  in  the  CG,  were
included  (Fig.  2).
There  were  no  signiﬁcant  differences  between  com-
pleters  and  dropouts  in  terms  of  age  (p  =  0.551)  and  gender
(p  =  0.303).  Participants’  characteristics  are  summarised  in
Table  1.  No  signiﬁcant  differences  were  observed  between
groups  at  baseline  (p  >  0.05).
All  patients  in  the  EG  completed  the  full  PR  programme
(i.e.,  6/6  sessions,  attendance  =  100%)  and  no  adversePlease  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol
events  were  reported.
After  the  community-based  PR  programme,  signiﬁcant
improvements  were  found  in  the  EG  in  symptoms  of  dysp-
noea  at  rest  (Pre  3  [0.5;  3.8]  vs.  Post  1  [0.0;  2.8],  p  =  0.008),
A
v
d
pntinued)
espiratory  rate  (Pre  24  [20.5;  27]  vs.  Post  20.5  [18;  23.5],
 =  0.004),  SpO2 (Pre  94  [89.3;  96]  vs.  Post  96  [94.3;  96],
 =  0.031),  quadriceps  muscle  strength  (Pre  21  [19.7;  27.2]
s.  Post  25  [22.4;  28.8],  p  =  0.012)  and  CAT  score  (Pre  23
19.3;  24.8]  vs.  Post  14.5  [6.3;  19.5],  p  =  0.008).  No  dif-
erences  were  found  in  the  remaining  outcome  measures
p  >  0.05).  The  CG  did  not  present  any  signiﬁcant  differences
fter  the  intervention  (Fig.  3).
In  the  between  groups  comparison,  the  EG  showed  signif-
cant  improvements  when  compared  to  the  CG  in  respiratory
ate  (EG  −3.5  [−4;  −0.5]  vs.  CG  2  [0;  4],  p  =  0.015),  quadri-
eps  muscle  strength  (EG  3.1  [1.9;  7.2]  vs.  CG  −0.5  [−2.8;
.4],  p  =  0.021)  and  CAT  (EG  −6  [−15;  −4.0]  vs.  CG  0  [−8;
],  p  =  0.013).  No  additional  differences  were  found  (Fig.  3).
There  was  a  signiﬁcantly  higher  number  of  patients
mproving  above  the  MCID  of  CAT  in  the  EG  than  in  the  CG
EG  11  vs.  CG  5,  p  = 0.027).  No  differences  were  found  for
he  remaining  outcome  measures.
None  of  the  patients,  either  in  the  EG  or  in  the  CG,
eeded  to  be  hospitalised  or  made  unscheduled  use  of  the
ealthcare  services  during  the  3 weeks  of  intervention.
iscussion
his  quasi-experimental  pilot  study  showed  that  community-
ased  PR  might  be  effective  during  mild-to-moderate.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
ECOPD.  Signiﬁcant  improvements  were  found  in  symptoms,
ital  signs,  quadriceps  muscle  strength  and  impact  of  the
isease  and  no  adverse  events  were  reported.  However,
atients  were  allowed  to  choose  their  group  allocation.
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Table  1  Sample  characterisation  (n  =  23).
Characteristics  Experimental  group  (n  =  12)  Control  group
(n  =  11)
p-Value
Age,  years  68.6  ±  7.4  65.8  ±  8.8  0.42
Gender, n  (%)
Male
Female
10  (83.3)
2 (16.7)
9  (81.8)
2  (18.2)
1.00
BMI, kg/m2 26.8  ±  3.2  27.6  ±  5.5  0.69
Smoking status,  n  (%)
Current
Former
Never
1  (8.3)
9 (75.0)
2  (16.7)
3  (27.3)
6  (54.5)
2  (18.2)
0.60
Pack-years 26.5  [2.7;  57.5]  27.0  [7.4;  60.0]  0.75
Exacerbations/previous  year  2.0  [1.0;  1.8]  1.0  [0.0;  2.0]  0.25
FEV1,  L  1.3  ±  0.7  1.4  ±  0.5  0.73
FEV1,  %predicted  51.5  ±  26.6  55.0  ±  21.5  0.74
FVC, L  2.7  ±  0.7  2.6  ±  0.7  0.83
FVC, %predicted  81.6  ±  24.6  78.5  ±  18.5  0.73
FEV1/FVC,  %  48.3  ±  16.8  53.1  ±  12.0  0.44
GOLD stages,  n  (%)
I
II
III
IV
3  (25.0)
3 (25.0)
4 (33.3)
2 (16.7)
2  (18.2)
4  (36.4)
3  (27.3)
2  (18.2)
1.00
GOLD groups,  n  (%)
A
B
C
D
1  (8.3)
3 (25.0)
1 (8.3)
7  (58.3)
3  (27.3)
3  (27.3)
1  (9.1)
4  (36.4)
0.68
Brief physical  activity  assessment
tool
0.0  [0.0;  7.3]  0.0  [0.0;  0.0]  0.07
Non-invasive ventilation,  n  (%)  3  (25.0)  2  (18.2)  1.00
Long-term oxygen  therapy,  n  (%)  3  (25.0)  2  (18.2)  1.00
CCI, n  (%)
Mild
Moderate
Severe
1  (8.3)
9 (75.0)
2 (16.7)
3  (27.3)
6  (54.5)
2  (18.2)
0.60
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Table  1  (Continued)
Characteristics  Experimental  group  (n  =  12) Control  group
(n  =  11)
p-Value
Medication  use,  n  (%) Stability  AECOPD
(extra)
Stability  AECOPD
(extra)
Stability
0.20
Antibiotics 1  (8.3) 5  (41.7) 1  (9.1) 9  (81.8) AECOPD
1.00
Antihistaminic  0  (0.0) 2  (16.7) 0  (0.0) 0  (0.0)
Antipyretics 0  (0.0) 1  (8.3) 3  (27.3) 2  (18.2)
Antitussive 0  (0.0) 0  (0.0) 0  (0.0) 1  (9.1)
Bronchodilators
Beta-adrenergic  agonists 4  (33.3) 0  (0.0) 3  (27.3) 0  (0.0)
Cholinergic antagonists 9  (75.0) 0  (0.0) 3  (27.3) 1  (9.1)
Anti-inﬂammatory  5  (41.7)  1  (8.3)  2  (18.2)  1  (9.1)
Xanthines 6  (50.0)  0  (0.0)  1  (9.1)  0  (0.0)
Associations of  bronchodilators
with  cholinergic  antagonists
10  (83.3)  2  (16.7)  5  (45.5)  3  (27.3)
Corticosteroids  0  (0.0)  2  (16.7)  0  (0.0)  1  (9.1)
Expectorants  3  (25.0)  5  (41.7)  1  (9.1)  5  (45.5)
mMRC score  2.5  [1.3;  3.0]  2.0  [1.0;  3.0]  0.84
Heart rate,  bpm  76.0  [74.0;  95.0]  82.0  [67.0;  91.0]  0.85
Respiratory rate,  cpm  24.0  [20.5;  27.0]  20.0  [18.0;  24.0]  0.06
SpO2,  %  94.0  [89.3;  96.0]  93.0  [92.0;  94.0]  0.46
Dyspnoea score,  mBorg  3.0  [0.5;  3.8]  3.0  [0.0;  4.0]  0.86
Fatigue score,  mBorg  3.0  [0.9;  6.3]  0.0  [0.0;  3.0]  0.09
Quadriceps muscle  strength,  kgf  21.0  [19.7;  27.2]  18.8  [17.4;  20.9]  0.10
5-Repetition sit-to-stand,  s 9.4  [6.9;  13.0]  7.6  [5.6;  9.8]  0.24
CAT total  score  23.0  [19.3;  24.8]  21.0  [14.0;  28.0]  0.89
Values are presented as mean ± standard deviation or median [interquartile range], unless otherwise stated.
Legend: AECOPD, acute exacerbation of chronic obstructive pulmonary disease; BMI, body mass index; bpm, beats per minute; CAT, COPD assessment test; CCI, Charlson comorbidity
index; cpm, cycles per minute; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mBorg, modiﬁed
Borg scale; mMRC, modiﬁed British Medical Research Council questionnaire; SpO2, peripheral oxygen saturation.
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sFigure  2  Flow  diagram  of
Symptoms  are  key  features  of  COPD41 and  have  been  con-
idered  important  outcomes  of  PR  during  exacerbations.3,42
n  this  study,  after  PR  there  was  a  signiﬁcant  decrease  in
yspnoea  levels  at  rest  and  most  patients  improved  above
he  MCID  in  the  mMRC  and  mBorg.  Nevertheless,  although
ositive  improvements  have  been  found  for  the  EG,  there
ere  no  signiﬁcant  differences  in  between  group  compar-
sons,  which  is  probably  related  with  the  small  sample  size.
urthermore,  no  signiﬁcant  improvements  have  been  found
or  fatigue,  possibly  because  of  the  relatively  low  baseline
atigue  scores  found  in  our  patients.  These  results  must  be
arefully  interpreted  as  dyspnoea  and  fatigue  are  multifac-
orial  symptoms  that  should  be  described  considered  as  both
atients’  subjective  perception  and  a  performance  compo-
ent,  and  the  mMRC  and  the  mBorg  are  unidimensional  tools
hat  measure  only  a  speciﬁc  moment  and  were  applied  at
est.43,44 Therefore,  these  instruments  might  have  failed  to
apture  dyspnoea  and  the  overall  impact  of  fatigue.  Mul-
idimensional  and  disease-speciﬁc  scales  should  be  used  in
uture  studies  to  allow  a  multifactorial  assessment  of  these
ymptoms  and  contribute  to  a  better  understanding  of  their
ehaviour  during  a  PR  programme  in  AECOPD.45 Moreover,
he  available  MCIDs  for  the  mMRC  and  the  mBorg  have  beenPlease  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol
stablished  for  patients  with  AECOPD  receiving  standard
f  care.32 Future  studies  exploring  MCIDs  for  patients  with
ECOPD  undergoing  PR  are  needed  to  better  understand  the
dded  value  of  this  intervention.
i
cicipants  through  the  study.
Despite  the  importance  of  assessing  symptoms  individ-
ally,  it  is  their  combination  that  impacts  on  patients’
RQoL,9,41 hence  a  comprehensive  symptom  assessment  is
ecessary.1 CAT  is  a  short,  simple,  multidimensional  and
asy  to  administer  questionnaire  that  has  been  developed  to
over  the  most  burdensome  symptoms  and  limitations  per-
eived  by  patients.46 Recent  literature  has  shown  that  CAT
s  responsive  to  treatment47,48 and  provides  relevant  prog-
ostic  information,49 therefore  its  use  to  assess  PR  during
ECOPD  has  been  advocated.9,47 In  this  study,  the  signiﬁcant
mprovements  and  number  of  patients  improving  above  the
CID  show  that  CAT  is  sensitive  to  changes  and  supports  its
outine  use  in  clinical  practice.
Vital  signs  and  SpO2 are  measures  previously  used  in
R  programmes  conducted  in  hospitalised  patients  with
ECOPD  and  improvements,  or  patterns  of  improvement,
ave  been  reported,50--53 suggesting  that  PR  is  a  safe
pproach  during  AECOPD.  This  pilot  study  corroborates  these
ndings  for  PR  implemented  in  the  community.  No  adverse
vents  were  reported;  however,  a  systematic  assessment  of
dverse  events  was  not  conducted.  Future  studies  should
arefully  assess  occurrence  of  adverse  events  and  the  need
or  unscheduled  healthcare  visits  during  and  after  each  ses-
ion  of  PR  to  establish  effectiveness  and  safeness  of  this.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
ntervention.
Quadriceps  muscle  weakness  is  a  well-known  systemic
onsequence  of  COPD1 that  affects  patients’  HRQoL  and
Please  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol.  2019.  https://doi.org/10.1016/j.pulmoe.2019.05.004
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Figure  3  Median  difference  and  interquartile  range  Pre/Post  the  intervention  per  group  in:  (a)  the  modiﬁed  British  Medical
Research Council  dyspnoea  questionnaire  (mMRC);  (b)  heart  rate  (beats  per  minute,  bpm);  (c)  respiratory  rate  (cycles  per  minute,
cpm); (d)  peripheral  oxygen  saturation  (SpO2);  (e)  symptoms  of  dyspnoea  at  rest  in  the  modiﬁed  Borg  scale  (mBorg);  (f)  symptoms
of fatigue  at  rest  in  the  modiﬁed  Borg  scale  (mBorg);  (g)  quadriceps  muscle  strength;  (h)  the  5-repetition  sit-to-stand  test  (5-STS);
and (i)  the  COPD  assessment  test  (CAT)  total  score.
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0  
urvival.54 During  AECOPD  there  is  a  more  accentuated
ecline  in  muscle  function,  resulting  in  long-term  losses
n  functional  capacity.55 This  study,  similarly  to  previous
esearch,  has  shown  that  PR  can  prevent  muscle  dys-
unction  by  improving  quadriceps  muscle  strength  during
ECOPD,13,54,56,57 thus  becoming  a  key  intervention  to  man-
ge  peripheral  muscle  weakness  and  prevent  further  clinical
ecline.
It  has  been  recognised  that  functionality,  a  vital  out-
ome  for  patients’  daily  life,  is  severely  impaired  during
ECOPD.41,58 In  this  study,  no  differences  were  found  in
atients’  functionality  after  PR.  This  ﬁnding  is  likely  to  be
ue  to  the  ceiling  effect  observed  in  the  5-STS  and  not  to
he  ineffectiveness  of  the  intervention.  At  baseline,  patients
lready  presented  a  good  functional  status  as  they  were
erforming  the  test  below  the  cut  off  for  risk  of  falling
i.e.,  12  s),59 so  with  little  room  for  improvement.  Given
he  importance  of  this  outcome,  further  research  on  the
ost  appropriate  outcome  measure  to  assess  functionality
n  patients  with  AECOPD  is  needed.
This  study  presents  some  limitations  that  need  to  be
cknowledged.  Firstly,  patients  were  not  randomised  and
ssessors  were  not  blinded.  However,  efforts  were  made
o  minimise  the  risk  of  bias  by  ensuring  that  patients
haracteristics  at  baseline  were  similar  and  implement-
ng  a  well-deﬁned  assessment  protocol  and  standardised
ntervention.  Secondly,  physical  activity  levels  were  not
onitored  during  the  AECOPD  and  it  is  possible  that  patients
illing  to  participate  in  the  PR  programme  were  also  more
illing  to  be  physically  active.  Nevertheless,  baseline  phys-
cal  activity  levels  were  no  different  between  the  groups.
e  registered  however,  a  higher  drop-out  rate  in  the  con-
rol  group,  probably  due  to  patients’  lack  of  motivation60
nd  lack  of  perceived  beneﬁt  of  their  participation.15 It
s  known  that  patients  who  have  chosen  not  to  attend
R  are  also  less  likely  to  participate  in  respiratory-related
esearch61 and,  thus,  more  likely  to  drop  out.  Third,  phar-
acological  treatment  was  not  standardised,  but  rather
rescribed  according  to  pulmonologists’  best  judgement  of
atients’  clinical  condition.  Although  no  differences  have
een  found  regarding  medication  on  baseline  assessment,  it
ust  be  acknowledged  that  different  combinations  of  drugs
ight  have  inﬂuenced  patients’  recovery.  Fourth,  exercise
apacity,  which  is  a  key  outcome  of  PR,  was  not  assessed
n  this  study  due  to  lack  of  space  to  perform  commonly
sed  ﬁeld  exercise  capacity  tests  (e.g.,  six-minute  walk
est  and  incremental  shuttle  walk  test)  at  patients’  home,
lthough  aerobic  training  was  performed.  Future  studies
hould  explore  the  effects  of  community-based  PR  during
ECOPD  on  patients’  exercise  capacity  using  alternative
eld-tests.  Since  informative  and  promising  results  were
btained,  there  is  now  the  need  to  adjust  the  outcome
easures  used  and  personalise  PR  to  patients’  needs,  in  a
andomised  controlled  trial.
onclusionsPlease  cite  this  article  in  press  as:  Machado  A,  et  al.  Pulmonol
ommunity-based  PR  seems  feasible  and  offers  promise
o  provide  timely  and  effective  management  of  patients
ith  mild-to-moderate  AECOPD.  The  addition  of  PR  to  stan-
ard  of  care  resulted  in  improvements  in  respiratory  rate, PRESS
A.  Machado  et  al.
ymptoms,  quadriceps  muscle  strength  and  impact  of  the
isease,  parameters  usually  associated  with  an  increased
isk  of  AECOPD  recurrence  and  poor  prognosis,37,62,63 and  no
dverse  events  reported.  Future  research  should  focus  on
andomised  studies  with  larger  samples  to  clarify  the  role  of
ommunity-based  PR  during  AECOPD.
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